

Anti-PD-1 /CTLA-4 Antibody (Cadonilimab)

Introduction

Cadonilimab is a bispecific antibody developed by a Chinese biopharmaceutical company. It consists of two fragments of monoclonal antibodies, targeting PD-1 and CTLA-4 respectively. By blocking these two immune checkpoints at the same time, Cadonilimab is able to enhance the anti-tumor activity of T cells and is mainly used to treat various types of cancer.

Product parameters

Alternative Names	AK104
Target Accession	-
Target	PD-1 /CTLA-4
CAS number	2394841-59-7
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

